β2-AR signaling controls trastuzumab resistance-dependent pathway (Q38896403)

7 September 2017

β2-AR signaling controls trastuzumab resistance-dependent pathway (English)

1 reference

7 September 2017

1 reference

D Liu

1

1 reference

7 September 2017

Z Yang

2

1 reference

7 September 2017

T Wang

3

1 reference

7 September 2017

Z Yang

4

1 reference

7 September 2017

H Chen

5

1 reference

7 September 2017

Y Hu

6

1 reference

7 September 2017

C Hu

7

1 reference

7 September 2017

L Guo

8

1 reference

7 September 2017

Q Deng

9

1 reference

7 September 2017

Y Liu

10

1 reference

7 September 2017

M Yu

11

1 reference

7 September 2017

M Shi

12

1 reference

7 September 2017

N Du

13

1 reference

7 September 2017

N Guo

14

1 reference

7 September 2017

language of work or name

English

0 references

publication date

23 March 2015

1 reference

7 September 2017

1 reference

7 September 2017

35

1 reference

7 September 2017

47-58

1 reference

7 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2015.58

7 September 2017

0 references

cites work

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Improving treatment of HER2-positive cancers: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Molecular pathways: beta-adrenergic signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Central and peripheral nervous systems: master controllers in cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Autonomic nerve development contributes to prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Depression, social support, and beta-adrenergic transcription control in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Host factors and cancer progression: biobehavioral signaling pathways and interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

The sympathetic nervous system induces a metastatic switch in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

β2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Beta blockers and breast cancer mortality: a population- based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

G protein-coupled receptors: novel targets for drug discovery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FONC.2015.58

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/25798840

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Characterizing distress, the 6th vital sign, in an oncology pain clinic

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Stress-induced immune dysfunction: implications for health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Stress and breast cancer: from epidemiology to molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

HER2-dependent MMP-7 expression is mediated by activated STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Expanding Our Therapeutic Options: Beta Blockers for Breast Cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Targeted therapies: Using β-blockers to inhibit breast cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.58

Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25798840

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Behavioral stress accelerates prostate cancer development in mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25798840

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2015.58

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference